Parkside Financial Bank & Trust’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$316K Buy
4,890
+1,131
+30% +$79.7K 0.02% 346
2025
Q4
$253K Buy
3,759
+111
+3% +$7.47K 0.02% 394
2025
Q3
$268K Sell
3,648
-367
-9% -$24.4K 0.02% 381
2025
Q2
$209K Sell
4,015
-144
-3% -$8.19K 0.02% 419
2025
Q1
$265K Buy
4,159
+2,359
+131% +$137K 0.03% 336
2024
Q4
$86.1K Buy
1,800
+322
+22% +$16.5K 0.01% 624
2024
Q3
$84.6K Buy
1,478
+232
+19% +$13.3K 0.01% 601
2024
Q2
$65.2K Sell
1,246
-620
-33% -$27.2K 0.01% 647
2024
Q1
$75.9K Buy
1,866
+133
+8% +$4.99K 0.01% 605
2023
Q4
$64.1K Buy
+1,733
New +$65.3K 0.01% 613

Other funds holding HALO

Parkside Financial Bank & Trust's HALO Position: Q1 2026 in Review

Parkside Financial Bank & Trust increased its Halozyme (HALO) stake by 30% in Q1 2026, buying an estimated $79.7K and bringing the position to 4,890 shares worth $316K. The position accounts for 0.02% of the portfolio, ranked #346.

Parkside Financial Bank & Trust first reported a position in HALO in Q4 2023 and has held it in 10 quarters since. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Parkside Financial Bank & Trust held 4,890 shares of Halozyme worth $316K as of Q1 2026.
  • Parkside Financial Bank & Trust bought 1,131 Halozyme shares in Q1 2026, an estimated $79.7K.
  • Halozyme made up 0.02% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #346 holding.
  • Parkside Financial Bank & Trust first reported a position in Halozyme in Q4 2023 and has held it in 10 quarters since.
  • 635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.